IGFL2 and primary cutaneous T-cell non-Hodgkin lymphoma: In line, IGFL2 has previously been described as a marker overexpressed in Sézary cells [32], and KIR3DL2 [71] is currently being investigated in clinical trials as therapeutic target for CTCL, showing early promising results [72].